When was Salarius Pharma founded?

Salarius Pharma was founded in 2010 and raised its 1st funding round within a year of its incorporation.

Where is Salarius Pharma located?

Salarius Pharma is headquartered in Houston, United States.

How many employees does Salarius Pharma have?

As of May 31, 2026, the latest employee count at Salarius Pharma is 10.

Is Salarius Pharma a funded company?

Salarius Pharma is a funded company, having raised a total of $108K across 8 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jul 30, 2010.

When was the latest funding round of Salarius Pharma?

Salarius Pharma's latest funding was a $***** Post IPO round on May 12, 2023, with participation from 0 investor. Its primary sector is Oncology. In United States, the Oncology sector has seen $2.85B in funding in 2026 to date.

What is the annual revenue of Salarius Pharma?

Annual revenue of Salarius Pharma is between $1M and $10M as on Dec 31, 2021

Where does Salarius Pharma rank among its competitors?

Salarius Pharma ranks 446th amongst 3272 active competitors, of which 1116 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Salarius Pharma?

Salarius Pharma's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

Salarius Pharma - 2026 Company Profile, Funding, Competitors & Financials

Salarius Pharma is a public company based in Houston (United States), founded in 2010. It operates as a Biopharmaceutical firm pioneering targeted protein inhibition and degradation cancer therapies. Salarius Pharma has raised $108K in funding. The company has 3272 active competitors, including 1116 funded and 774 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Biopharmaceutical firm pioneering targeted protein inhibition and degradation cancer therapies. This clinical-stage company is dedicated to developing innovative therapies for cancer patients with unmet needs, focusing on correcting dysregulated gene expression in cancer cells. The company develops targeted protein inhibitors and targeted protein degraders to address gene dysregulation, potentially impacting solid and hematologic cancers. Their lead protein inhibitor is in phase 1/2 trials, and a targeted protein degrader is in IND-enabling studies. The company aims to positively influence the lives of patients with cancers like leukemias and lymphomas. This innovative approach represents a potential paradigm shift in cancer treatment, offering new hope for patients in need of advanced therapeutic options.

Website: salariuspharma.com
Email ID: *****@salariuspharma.com

Key Metrics

Founded Year

2010

Location

Houston, United States

Stage

Public

Total Funding

$108K in 8 rounds

Latest Funding Round

Post IPO, May 12, 2023, $*****

Investors

Aspire Capital & 10 more

Ranked

446^th among 3272 active competitors

Annual Revenue

$1M - $10M as on Dec 31, 2021

Employee Count

10 as on May 31, 2026

Investment & Acquisitions

Decoy

Similar Companies

Jazz Pharmaceuticals & 2976 more

Exit Details

Public

View Salarius Pharma's full profile

Salarius Pharma is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Flex Pharma, Inc. CIN: 1615219 , United States, Active	Sep 08, 2021	$1M - $10M (As on Dec 31, 2021)	34 (As on Dec 31, 2016)	-

Salarius Pharma got listed on Jul 27, 2018.

Click here to take a look at Salarius Pharma's IPO in detail

Salarius Pharma has raised a total funding of $108K over 8 rounds. Its first funding round was on Jul 30, 2010. Salarius Pharma has 11 institutional investors.

Here is the list of recent funding rounds of Salarius Pharma:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 12, 2023	2823719	Post IPO	4324647	6994874	8606007	2443541
Feb 16, 2023	4269258	Grant (prize money)	2873090	2967939	3756859	state.tx.us
Apr 25, 2022	1732660	Post IPO	3955796	2875187	2676392	1604298

Access funding benchmarks and valuations. Sign up today!

View details of Salarius Pharma's funding rounds and investors

Salarius Pharma's employee count trend

Salarius Pharma has 10 employees as of May 26. Here is Salarius Pharma's employee count trend over the years:

Employee count trend for Salarius Pharma

Uncover Salarius Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Salarius Pharma include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Salarius Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, F-Prime Capital & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
446th	Salarius Pharma 2010, Houston (United States), Public	Biopharmaceutical firm pioneering targeted protein inhibition and degradation cancer therapies	$108K	Aspire Capital, Green Park & Golf Ventures ... & 9 others	54/100